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Infection of dogs with canine inﬂuenza virus (CIV) is considered widespread throughout the United States following the ﬁrst
isolation of CIV in 2004. While vaccination against inﬂuenza A infection is a common and important practice for disease control,
antiviral therapy can serve as a valuable adjunct in controlling the impact of the disease. In this study, we examined the antiviral
activity of nitazoxanide (NTZ) and tizoxanide (TIZ) against three CIV isolates in vitro. NTZ and TIZ inhibited virus replication of
all CIVs with 50% and 90% inhibitory concentrations ranging from 0.17 to 0.21µM and from 0.60 to 0.76µM, respectively. These
results suggest that NTZ and TIZ are eﬀective against CIV and may be useful for treatment of canine inﬂuenza in dogs but further
investigation of the in vivo eﬃcacy against CIV as well as the drug’s potential for toxicity in dogs is needed.
1.Introduction
In 2004, canine inﬂuenza virus (CIV) was ﬁrst isolated
from the lung tissue of a racing greyhound dog that had
died of pneumonia [1]. Since its ﬁrst isolation, the virus
has spread into the nongreyhound dog population and has
caused outbreaks of respiratory disease in dogs throughout
the United States [1–3]. As the virus is transmitted in
aerosols created by coughing and sneezing, close contact
and closed environments favor virus spread. Thus, the
highest incidence of infection is found in dogs that are
housed in groups, such as at humane shelters [2, 3].
While most dogs infected with CIV have generally mild
illness, a small percentage of dogs develop a more severe
form of disease characterized by persistent fever, lethargy,
dyspnea, and clinical signs of bronchopneumonia [3].
Vaccination is an important practice for the control of
inﬂuenza infection in many species. Despite the fact that a
conditionally licensed, inactivated CIV vaccine has recently
become available for use in the United States (Canine
Inﬂuenza Vaccine, Intervet/Schering-Plough Animal Health,
Summit, NJ), it is currently unknown how eﬀective vacci-
nation will be in preventing disease in dogs. Moreover, as
eﬀective immunoprotection through active immunization
typically requires the administration of several doses of
the target antigen (priming and booster doses), vaccination
may not represent a realistic approach to confer protection
to the transient canine populations housed at humane
shelters.
In contrast, antiviral therapy could represent a viable
option for the immediate protection of dogs during canine
inﬂuenza outbreaks, as antiviral drugs do not rely on the
i n d u c t i o no fap r o t e c t i v ei m m u n er e s p o n s e[ 4]. Antiviral
agents also represent a potential inﬂuenza virus-speciﬁc
treatment option. A number of animal shelters have
employed oseltamivir phosphate (TamiFlu, Roche, Basel,
Switzerland) for treatment of dogs during CIV outbreaks.
Despite this, the use of oseltamivir phosphate in dogs is
not recommended as the dose, duration of treatment, safety,
as well as the eﬃcacy of this drug against CIV isolates
are unknown [3]. More importantly, oseltamivir should be
reserved as a vital defense for the protection of human health
during an inﬂuenza pandemic. Several studies have demon-
strated that the use of antiviral drugs can result in the devel-
opment of antiviral resistance among inﬂuenza A viruses.
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the eﬀectiveness of treatment during an inﬂuenza pandemic
[5–8].
Nitazoxanide (NTZ), a thiazolide compound, has been
shown to have antimicrobial activity against a variety of
parasites, anaerobic bacteria, and viruses [9–13]. The drug is
labeledfortreatmentofinfectiousenteritiscausedbyGiardia
lamblia and Cryptosporidium parvum in humans and for
the treatment of equine protozoal myeloencephalitis (EPM)
in horses. NTZ has moderate oral bioavailability and, once
absorbed, the compound is hydrolyzed in plasma to form
the active metabolite tizoxanide (TIZ). NTZ is generally
well tolerated and the most commonly reported side eﬀects
include mild abdominal pain, nausea, and diarrhea. The
compound has been found eﬀective for the treatment of
rotavirus and norovirus gastroenteritis in human clinical
trials [14, 15]. While the mechanism for its broad-spectrum
a n t i v i r a la c t i v i t yi sn o tf u l l yu n d e r s t o o d ,i ti sm o s tl i k e l y
mediated by a cell-speciﬁc rather than a virus-speciﬁc
eﬀect. This notion is supported by ﬁndings of a recent
study that demonstrated that NTZ inhibited replication of
several human- and avian-lineage inﬂuenza A virusesinvitro
possibly by blocking traﬃcking of the viral hemagglutinin
(HA) protein between the endoplasmic reticulum and the
Golgi complex [16]. Taken together, these data suggest that
NTZ may be a valuable treatment for dogs infected with CIV,
provided that the drug also has inhibitory activity against
canine inﬂuenza viruses. In this report, we present results of
in vitro studies characterizing the activities of NTZ and TIZ
against three recent canine inﬂuenza virus isolates.
2.MaterialsandMethods
2.1. Inﬂuenza Viruses. Field isolates of A/Canine/Colorado-
1/224986/06 (Ca/CO-1), A/Canine/Colorado-3/3/06 (Ca/
CO-3), and A/Canine/Colorado-4/2025974/07 (Ca/CO-4)
(all H3N8) were cultivated in Madin-Darby canine kidney
(MDCK) cells as previously described in [17]. To conﬁrm
sequence identity, the full-length protein coding regions of
the HA and neuraminidase (NA) genes of Ca/CO-1, Ca/CO-
3, and Ca/CO-4 were ampliﬁed by RT-PCR and sequenced as
previously described in [18].
2.2. Determination of Cell Toxicity. Nitazoxanide (NTZ) was
provided by IDEXX Laboratories (Westbrook, ME, USA)
and tizoxanide (TIZ) was provided by Romark Laboratories
(Tampa, FL, USA). Stock solutions were prepared by dis-
solving 50mg NTZ or TIZ in 1mL of dimethyl sulfoxide
(DMSO), divided into aliquots, and stored at −80◦C. Work-
ingsolutionsofNTZandTIZwerepreparedfreshbydiluting
the stock solution to the appropriate µM concentration in
MEM supplemented with 100IU penicillin/streptomycin,
100 mM L-glutamine, 0.5% bovine serum albumin (GIBCO,
Carlsbad, CA, USA) and 1µg/mL tolylsulfoyl phenylalanyl
choromthyl ketone-(TPCK-) treated trypsin (Worthington
Biochemical Corporation, Lakewood, NJ, USA). Working
solutions of NTZ or TIZ were then added to a conﬂuent
monolayer of MDCK cells in 96-well tissue culture plates
(BD Biosciences, San Jose, CA, USA). Negative (no NTZ
or TIZ) and DMSO (1%) control samples were included in
eachexperiment.Plateswerethenincubatedat37◦Cwith5%
CO2. Cell cytotoxicity of NTZ and TIZ was determined after
96 hours using the alamar blue reduction assay by methods
previously described [19]. Cell viability was expressed as the
CC50, which is the Cytotoxic Concentration at which a 50%
decrease in alamarblue reduction was noted whencompared
to the negative control.
2.3.DeterminationofNTZandTIZInhibitoryConcentrations.
Conﬂuent monolayers of MDCK cells cultured in 96-
well tissue culture plates were infected at a multiplicity
of infection (MOI) of 0.001 with Ca/CO-1, Ca/CO-3, or
Ca/CO-4. Infected plates were incubated with agitation for
2 hours at 37◦Cw i t h5 %C O 2. After incubation, the virus
inoculum was removed and 200µL of working solutions of
NTZ or TIZ, at concentrations ranging from 0.001µMt o
4.0µM, were added to each well. Positive (no NTZ or TIZ)
and negative (no virus) control samples as well as a 1%
DMSO control were included in each experiment. Plates
were then incubated at 37◦Cw i t h5 %C O 2 for 72 hours.
The virus titer in cell culture supernatants of each well,
expressed as tissue culture infective dose (TCID)50 per mL,
was calculated using the method of Reed and Muench as
previously described [17].
2.4. Statistical Analysis. Each experiment was done on 3
diﬀerent occasions with 8 samples of each NTZ or TIZ
concentration per replicate (n = 24). The amount of infec-
tious CIV in the treated culture supernatant was expressed
as a percentage of the control value and was calculated by
dividing the titer of each treated sample by the average of
the untreated positive control. To normalize the data, the
p e r c e n t a g ec o n t r o lv a l u e sw e r el o gt r a n s f o r m e d .T h ed a t a
was analyzed by polynomial regression analysis. Based on the
ﬁt and overall variance (R2), the best model was selected to
determine the antiviral eﬀective concentrations that result
in the 50% (EC50) and 90% (EC90) reduction of virus
titers in the culture supernatants. Selectivity index (SI) was
calculated by dividing the CC50 by the EC50. To evaluate the
association between the independent variables (dose, drug,
and strain) and the outcome variable (viral titer relative to
the control), the data was analyzed a multivariable linear
regression analysis with a mixed model approach PROC
MIXED (SAS v9.1, SAS Institute Incorporated, Cary, NC) by
specifying the ﬁxed and random eﬀects. A critical alpha for
all statistical analyses was set ap r i o r iat 0.05.
3. Results
Sequencing and phylogenetic analyses of the HA and NA
genes of the three canine inﬂuenza isolates used in this study
conﬁrmed that Ca/CO-1, Ca/CO-3, and Ca/CO-4 clustered
with the contemporary canine H3N8 inﬂuenza viruses,
placing them into the previously described distinct canine
sublineages of the equine H3 “Florida lineage” (Figure 1)
[2]. NTZ and its active metabolite TIZ exhibited dose-
dependent inhibition of extracellular virus production byVeterinary Medicine International 3
A/Ca/Colorado-3/06
A/Ca/Colorado-1/06
A/Ca/Colorado-4/06
A/Ca/Wyoming/86955/07
A/Ca/Weld/231256/07
A/Ca/Weld/2025974/07
A/Ca/Florida/242/03
A/Eq/Colorado/9/07
A/Eq/Colorado/10/07
A/Eq/Nebraska/824761/07
A/Eq/Florida/612/05
A/Eq/Florida/779/05
A/Eq/Wisconsin/1/03
A/Eq/Ohio/1/03
A/Eq/Kentucky/5/02
A/Eq/Florida/1/93
A/Eq/Kentucky/1/91
A/Eq/Miami/1/63
5 changes
A/Ca/Iowa/13628/05
A/Ca/FortCollins/224766/06
Figure 1: Phylogenetic relationships at the nucleotide level among
the hemagglutinin 3 (H3) genes of contemporary canine (including
Ca/CO-1, Ca/CO-3, and Ca/CO-4 used in this study) and equine
inﬂuenza viruses. Scale bar represents a diﬀerence at the nucleotide
level of 5%.
MDCK cells. Complete inhibition of in vitro replication of
Ca/CO-1, Ca/CO-3, and Ca/CO-4 in MDCK cells in the
presence of NTZ or TIZ was observed at a concentration of
5µM. At concentrations of NTZ or TIZ between 1 and 2µM,
replication of all three CIV isolates was partially inhibited
resulting in the reduction of virus titers by 3 log10 compared
to the control wells.
To determine EC50 and EC90, assays were performed
using NTZ or TIZ concentrations ranging from 0.001 to
2µM. Dose response curves for Ca/CO-1, Ca/CO-3, and
Ca/CO-4 viral titers are shown in Figure 2. The best model
selected with good ﬁt and 82% overall variance (R2)w a s
the Quadratic polynomial model. The multivariable linear
regression analysis, the selected model for the viral titers
with CIV strain Ca/CO-4 was signiﬁcantly higher (P<. 05)
than Ca/CO-1. The viral titers with CIV strain Ca/CO-4
were lower than Ca/CO-1 and Ca/CO-3 with P = .07.
However,thisdidnotresultinsigniﬁcantdiﬀerencesbetween
the EC50 and EC90 for the three viral isolates (Table 1). The
model also indicated that the viral titers with addition of
TIZ were signiﬁcantly higher (P<. 05) compared to those
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Figure 2: Eﬀe c to fN T Z( c l o s e d )o rT I Z( o p e n )a g a i n s tC I V
(Ca/CO-1 ( , Δ)C a / C O - 3(  ,  )a n dC a / C O - 4(  , ♦)) relative
to the replication of the untreated controls in MDCK cells.
with addition of NTZ. While the EC50 values for NTZ and
TIZ for the three CIV isolates (0.17–0.21µM) were similar
for each strain (Table 1), the EC90 values were consistently
3.5 times higher than the EC50 (0.60–0.76µM) regardless of
strain or drug form (NTZ or TIZ). In contrast, the selectivity
index of TIZ against all three CIV strains was double the
valueobtainedfortheparentcompoundNTZ(Table 1).This
was directly related to the CC50 values for NTZ and TIZ on
MDCK cells, which were 64.9µM and 130µM, respectively.
4. Discussion
The recent emergence of canine inﬂuenza virus represents
a serious threat to canine health and welfare. As dogs
possess no natural immunity against this virus, all dogs,
regardless of age, breed, or sex are potentially susceptible
to infection. While the total number of CIV infections that
have occurred since the appearance of the virus in 2004
is unknown, a recent one-year study performed by our
laboratory found CIV PCR-positive dogs in 11 of 16 (69%)
Colorado humane shelters that experienced outbreaks of
canine respiratory disease [20]. These results support the
importance of CIV as a cause of morbidity in shelter dogs
in the United States. Despite the fact that an inactivated
vaccine has recently become available, antiviral therapy may
be beneﬁcial in ﬂuctuating populations such as in shelters
because initial vaccination series for the canine vaccine
should include two doses. In this study, we report that
the thiazolide NTZ and its active metabolite TIZ possess
potent antiviral activities against three genetically distinct
canine inﬂuenza viruses. Inhibition of virus replication was
dose dependent and the concentrations of NTZ and TIZ
needed to inhibit CIV replication were comparable to the
concentrations found to be eﬀective against Hepatitis B
Virus and Hepatitis C Virus (HCV) (0.12–0.21µM) [21]
but lower than the concentrations needed to inhibit several
human inﬂuenza viruses and an avian isolate (1.63–3.25µM)
[16]. Several studies indicate that concentrations necessary4 Veterinary Medicine International
Table 1:In vitro activityofnitazoxanide(NTZ)anditsactivemetabolitetizoxanide(TIZ)onclinicalisolatesofcanineinﬂuenzavirus(CIV).
Virus Drug EC50 EC90 SI
Ca/CO-1 NTZ 0.20 ± 0.01 0.70 ± 0.03 331
TIZ 0.20 ± 0.01 0.72 ± 0.03 644
Ca/CO-3 NTZ 0.17 ± 0.01 0.60 ± 0.03 391
TIZ 0.17 ± 0.01 0.62 ± 0.03 751
Ca/Co-4 NTZ 0.20 ± 0.01 0.71 ± 0.03 329
TIZ 0.19 ± 0.01 0.70 ± 0.03 374
CIV NTZ 0.21 ± 0.02 0.76 ± 0.03 309
TIZ 0.21 ± 0.02 0.75 ± 0.03 619
EC50 or 90: Concentration (µM) of NTZ or TIZ at which a 2-fold (50%) or 10-fold (90%) reduction of viral titer is relative to untreated controls. EC50 and
EC90 are expressed as means ± standard deviation.
SI: Selectivity Index (CC50/EC50).
Viral titers of three CIV isolates were analyzed using polynomial regression analysis. 95% conﬁdence intervals for each value are displayed in parenthesis.
to inhibit CIV replication are readily achievable in plasma
following oral administration of NTZ to humans [22, 23]. In
humans, the drug is typically well tolerated and only mild,
and generally transient, adverse eﬀects have been reported
[23, 24]. In contrast, since the drug is also active against
microaerophilic and anaerobic bacteria that are a part of the
normal gastrointestinal ﬂora, substantial side eﬀects, such
as enterocolitis, have been described in horses following
administration of NTZ [25]. Since cytotoxic levels observed
in vitro do not necessarily indicate the actual toxicity of NTZ
in the animal, further research is needed to determine the
pharmacokinetics and safety of NTZ in dogs.
Currently, two classes of antiviral agents are available for
prophylaxisandtreatmentofinﬂuenzaAvirusinfections;the
M2 ion channel blockers and the neuraminidase inhibitors.
The M2 ion channel blockers amantadine and rimantadine
inhibit virus replication through allosteric inhibition of the
M2 protein, thus blocking the ﬂow of H+ ions from the
acidiﬁed endosomal compartment into the interior of the
virion.Theneuraminidaseinhibitors,oseltamivirphosphate,
andzanamivirblocktheactivesiteoftheviralneuraminidase
protein preventing the release of the inﬂuenza virion from
infected cells. Of these antivirals, oseltamivir phosphate is
currently considered the drug of choice for treatment of
inﬂuenza in humans. However, as resistance to oseltamivir
and the M2 ion channel blockers can be conferred by a single
pointmutation[26–28],antiviralresistanceamonginﬂuenza
A isolates is rapidly increasing [6, 29–31]. As the viral RNA
polymerase lacks proofreading function, inﬂuenza A viruses
demonstrate high mutations rates. Given the plasticity of
theinﬂuenzavirusgenome,selectivepressureswillinevitably
lead to mutational changes.
Unlike direct-acting antiviral drugs, NTZ does not
inhibit viral RNA transcription or block viral protein
synthesis, instead, the drug interferes with cellular posttran-
scriptional protein processing and may interfere with the
assembly of viral glycoproteins, preventing the formation
of mature viral particles [9, 21]. For example, NTZ has
been shown to inhibit the function of protein disulﬁde
isomerase [32], an important enzyme for three-dimensional
protein formation in the endoplasmic reticulum (ER). More
speciﬁcally, Rossignol and colleagues demonstrated that
NTZ exerts its anti-inﬂuenza eﬀects by interfering with
the maturation and the intracellular traﬃcking of the HA
protein [16]. Given the drug’s activity against a wide range of
viral pathogens, it has been speculated that NTZ’s antiviral
eﬀect is mediated by a cell-speciﬁc rather than a virus-
speciﬁc mechanism [16]. This hypothesis is supported by
the ﬁnding that transfection of HCV viral RNA isolated
from NTZ or TIZ-resistant replicon-containing cell lines did
not transfer NTZ or TIZ resistance, suggesting an absence
of acquired resistance in the HCV genome [33]. Taken
together, this suggests that the potential for the development
of antiviral resistance to NTZ by mutational adaptation of
the virus genome may be minimal.
5. Conclusions
Our results represent the ﬁrst report of the in vitro activity of
NTZ and its active metabolite TIZ against three genetically
distinct, contemporary canine inﬂuenza viruses. The use
of a broad-spectrum antiviral such as NTZ in conjunction
with supportive care may reduce the morbidity and risk of
secondary complications associated with canine inﬂuenza.
The use of NTZ as a prophylactic and therapeutic antiviral
during CIV outbreaks could possibly shorten the duration of
nasal virus shedding, thus limiting the spread of the virus.
However, further investigation of the in vivo eﬃcacy against
CIV as well as the drug’s potential for toxicity in dogs is
needed.
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